Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
Antigens, CD19
/ metabolism
Antigens, Neoplasm
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Culture Techniques
/ methods
Cell Engineering
/ methods
Cell Line, Tumor
Culture Media
Humans
Immunotherapy, Adoptive
/ methods
Interleukin-15
/ immunology
Interleukin-2
/ immunology
Interleukin-7
/ immunology
Membrane Proteins
/ immunology
Neoplasms
/ immunology
Receptors, Chimeric Antigen
/ genetics
Adoptive T cell transfer
Interleukin
NY-ESO-1
T cell receptor
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
26
10
2018
accepted:
03
06
2019
pubmed:
10
6
2019
medline:
6
7
2019
entrez:
10
6
2019
Statut:
ppublish
Résumé
The anti-tumor efficacy of TCR-engineered T cells in vivo depends largely on less-differentiated subsets such as T cells with naïve-like T cell (T
Identifiants
pubmed: 31177329
doi: 10.1007/s00262-019-02354-4
pii: 10.1007/s00262-019-02354-4
doi:
Substances chimiques
Antigens, CD19
0
Antigens, Neoplasm
0
CD19 molecule, human
0
CTAG1B protein, human
0
Culture Media
0
IL15 protein, human
0
IL2 protein, human
0
IL7 protein, human
0
Interleukin-15
0
Interleukin-2
0
Interleukin-7
0
Membrane Proteins
0
Receptors, Chimeric Antigen
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM